NCT02513563

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Carboplatin	Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
DRUG	Paclitaxel	Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
DRUG	AZD1775	Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

Timeline

• Start date: 2015-10-13
• Primary completion: 2022-11-27
• Completion: 2023-11-28
• First posted: 2015-07-31
• Last updated: 2026-02-19
• Results posted: 2024-01-10

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study